Northland Securities Comments on Nephros Q4 Earnings

Nephros Inc. (NASDAQ:NEPH) – Stock analysts at Northland Securities issued their Q4 2026 earnings per share estimates for Nephros in a report released on Thursday, August 13th. Northland Securities analyst B. Brooks forecasts that the company will post earnings of $0.01 per share for the quarter. Northland Securities currently has a “Market Perform” rating and a $4.00 target price on the stock. The consensus estimate for Nephros’ current full-year earnings is $0.03 per share.

Nephros (NASDAQ:NEPH) last announced its earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter. The company had revenue of $6.02 million during the quarter, compared to analysts’ expectations of $4.99 million. Nephros had a return on equity of 11.03% and a net margin of 8.38%.

A number of other brokerages have also recently weighed in on NEPH. Weiss Ratings upgraded shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 3rd. Zacks Research upgraded shares of Nephros to a “hold” rating in a research note on Monday, July 20th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $4.00.

Nephros Stock Performance

Shares of NEPH opened at $4.69 on Friday. The stock has a market capitalization of $50.93 million, a PE ratio of 29.31 and a beta of 1.51. Nephros has a 1 year low of $2.66 and a 1 year high of $6.42. The company’s 50-day simple moving average is $3.54 and its 200-day simple moving average is $3.51.

Institutional Trading of Nephros

A number of institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new stake in shares of Nephros during the 4th quarter worth about $29,000. Heron Bay Capital Management acquired a new position in shares of Nephros in the 4th quarter valued at $66,000. Dimensional Fund Advisors LP purchased a new position in shares of Nephros in the 3rd quarter valued at $64,000. Citadel Advisors LLC raised its stake in Nephros by 39.2% during the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after acquiring an additional 4,655 shares in the last quarter. Finally, De Lisle Partners LLP acquired a new position in Nephros in the second quarter valued at $62,000. 41.10% of the stock is owned by hedge funds and other institutional investors.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.